Business
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patient Start Forms, Conversion
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\n$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021)\n\nSteady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage\n\nAddition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline\n\nConference call to be hosted today at 8:30 a.m. ET\n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.\n\nAurinia achieved third quarter revenue of $14.7 million, with nine months ended September 30, 2021 revenue of $22.2 million and maintains its previously stated annual revenue estimate in the range of $40 to $50 million for 2021.\n\n“We are very pleased with Q3 results as we continue to execute on our LUPKYNIS commercialization strategies,” said Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Despite the challenge of the COVID-19 Delta variant and a slight seasonal slowdown, we saw steady increases in patient start forms and patients on treatment toward the end of the quarter and continue to see this upward momentum through October.”\n\n“Data presentations at key medical meetings this week, including additional interim results from the AURORA 2 continuation study, will help bolster awareness of and confidence in the efficacy and safety of LUPKYNIS and we expect final results of the continuation study to be announced by the end of 2021,” Greenleaf added.\n\n“Finally, while our commercial team focused on increasing adoption of LUPKYNIS, Aurinia recently added two exciting preclinical assets – AUR200 and AUR300,” said Greenleaf. “We are eager to leverage our expertise and capabilities to advance these compounds for the treatment of rare autoimmune diseases with high unmet needs.”\n\nThird Quarter 2021 Highlights & Upcoming Milestones:\n\n\nAurinia has secured 412 patient start forms (PSFs) in the third quarter and as of November 3, 2021, Aurinia has secured a total of more than 1,265 PSFs.\n\n\nPSF conversion rates continue to increase with more than 68% of PSFs converted to patients on therapy. Q2 conversion rates were 50%. Time to convert continues to decrease since launch: 30- and 60-...